Case involving senior dosimetrist at a premier cancer hospital in the Northeast suggests potential relevance of Phyto-N in one of oncology’s most ...

Curanex Pharmaceuticals Inc. CURX on Wednesday highlighted five additional patient cases that management believes further ...

Curanex Pharmaceuticals Inc. CURX on Monday said that a recent patient case study may reinforce its strategic push into ...

MUNICH--(BUSINESS WIRE)--CatalYm today announced new findings from its ongoing Phase 1/2a study as well as preclinical research, highlighting the therapeutic potential of its lead drug candidate, ...

NORTHBROOK, Ill.--(BUSINESS WIRE)--Endevica Bio, a company developing first-in-class peptide drug candidates with better safety and efficacy properties, has closed a $10 million Series B funding. The ...

Cachexia, defined as a loss of body weight, fat, and muscle mass that occurs in patients with chronic diseases, including cancer, remains a notable clinical challenge. With limited viable treatment ...

Company expands strategic focus into one of oncology’s most urgent supportive-care challengesJericho, New York, April 02, 2026 (GLOBE NEWSWIRE) ...

A new phase 2b/3 trial was approved to study of S-pindolol benzoate to treat cachexia, a wasting disease associated with cancer. The Food and Drug Administration (FDA) OKed phase 2b/3 trials to ...

A Remote Symptom Monitoring Tool As Part of Ambulatory Cancer Surgery Recovery: A Qualitative Analysis of Patient Experience Professional education and training programs on palliative care and cancer ...

SOLANA BEACH, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (ARTL) (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to ...

Eating disorders are often thought of as body image disorders with symptoms of food restriction and purging. In most cases, the goal of these behaviors is to prevent weight gain. Not all eating ...